The international study - a meta-analysis pooling results of 522
trials covering 21 commonly-used antidepressants and almost 120,000
patients - uncovered a range of outcomes, with some drugs proving
more effective than others and some having fewer side effects.
But all 21 drugs - including both off-patent generic and newer,
patented drugs - were more effective than placebos, or dummy pills,
the results showed.
"Antidepressants are routinely used worldwide yet there remains
considerable debate about their effectiveness and tolerability,"
said John Ioannidis of Stanford University in the United States, who
worked on a team of researchers led by Andrea Cipriani of Britain's
Oxford University.
Cipriani said these findings now offered "the best available
evidence to inform and guide doctors and patients" and should
reassure people with depression that drugs can help.
"Antidepressants can be an effective tool to treat major depression,
but this does not necessarily mean antidepressants should always be
the first line of treatment," he told a briefing in London.
According to the World Health Organization, some 300 million people
worldwide have depression. While both pharmacological and
psychological treatments are available, only one in six people with
depression in rich countries gets effective treatment. That drops to
one in 27 patients in poor and middle-income countries.
EFFECTIVENESS VARIES
The study, published in The Lancet medical journal, found some
differences in the effectiveness of the 21 drugs.
In general, newer antidepressants tended to be better tolerated due
to fewer side effects, while the most effective drug in terms of
reducing depressive symptoms was amitriptyline - a drug first
discovered in the 1950s.
[to top of second column] |
Some well-known medicines - such as the selective serotonin reuptake
inhibitor (SSRI) fluoxetine, sold under the Prozac brand - were
slightly less effective but better tolerated.
The scientists noted that their study could only look at average
effects, so should not be interpreted as showing that
antidepressants work in every patient. Only around 60 percent of
people prescribed depression medication improve, Cipriani said.
"Unfortunately, we know that about one third of patients with
depression will not respond to them," he said. "It's clear there is
still a need to improve treatments further."
Several experts not directly involved in the study said its results
gave a clear message.
"This meta-analysis finally puts to bed the controversy on
antidepressants," said Carmine Pariante, a professor at Britain's
Institute of Psychiatry, Psychology and Neuroscience.
James Warner, a psychiatrist at Imperial College London, added:
"Depression causes misery to countless thousands every year and this
study adds to the existing evidence that effective treatments are
available."
(Reporting by Kate Kelland; Editing by Gareth Jones)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|